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EFhd2 is a conserved calcium binding protein linked to different neurological disorders
and types of cancer. Although, EFhd2 is more abundant in neurons, it is also found
in other cell types. The physiological function of this novel protein is still unclear,
but it has been shown in vitro to play a role in calcium signaling, apoptosis, actin
cytoskeleton, and regulation of synapse formation. Recently, EFhd2 was shown to
promote cell motility by modulating the activity of Rac1, Cdc42, and RhoA. Although,
EFhd2’s role in promoting cell invasion and metastasis is of great interest in cancer
biology, this review focusses on the evidence that links EFhd2 to Alzheimer’s disease (AD)
and other neurological disorders. Altered expression of EFhd2 has been documented
in AD, Parkinson’s disease, Huntington’s disease, Amyotrophic Lateral Sclerosis, and
schizophrenia, indicating that Efhd2 gene expression is regulated in response to
neuropathological processes. However, the specific role that EFhd2 plays in the
pathophysiology of neurological disorders is still poorly understood. Recent studies
demonstrated that EFhd2 has structural characteristics similar to amyloid proteins found
in neurological disorders. Moreover, EFhd2 co-aggregates and interacts with known
neuropathological proteins, such as tau, C9orf72, and Lrrk2. These results suggest
that EFhd2 may play an important role in the pathophysiology of neurodegenerative
diseases. Therefore, the understanding of EFhd2’s role in health and disease could lead
to decipher molecular mechanisms that become activated in response to neuronal stress
and degeneration.
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INTRODUCTION
Efhd2 gene codes for a 26.8 kDa highly conserved protein, from nematodes to human, located
in chromosome 4 (4E1;4 74.75 cM) in mice and chromosome 1 (1p36.21) in humans. EFhd2
was first identified in a proteomics screen designed to discriminate CD8 from CD4 and CD19
lymphocytes. The abundance of this novel protein was found to be reduced in CD4 and C19
in comparison to CD8 lymphocytes (Vuadens et al., 2004; Dütting et al., 2011). In this original
study, the novel protein was named Swiprosin 1, in reference to the Swiss-Prot database used
for the tandem mass spectrometry data analysis (Vuadens et al., 2004). Subsequently, the name
of this novel protein was changed to EF-hand domain family, member D2 (EFhd2) due to the
presence of two EF-hand calcium binding motifs. Characterization of EFhd2 demonstrated that it
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is an ubiquitous calcium binding protein, preferentially expressed
in the central nervous system (Avramidou et al., 2007; Vega et al.,
2008; Hagen et al., 2012; Ferrer-Acosta et al., 2013b). Further
sequence analyses indicated that EFhd2 has a coiled-coil domain
at the C-terminus, which is a conserved domain among fibrillar
proteins and required for protein–protein interaction (Ferrer-
Acosta et al., 2013a). At the N-terminus, EFhd2 has a distinctive
polyalanine motif that varies in size (between 6 and 9 alanines)
and it is only present in mammals (Dütting et al., 2011; Ferrer-
Acosta et al., 2013a). The function of EFhd2’s polyalanine motif
is still unknown, but proteins containing polyalanine expansions
have been shown to be linked to different neurological disorders
(Albrecht and Mundlos, 2005). However, the physiological and
pathological roles of EFhd2 are still poorly understood.
EFhd2 may function as a signaling or cytoskeleton regulatory
protein. In WEHI231 cells, it was shown that EFhd2 is required
for the regulation of the canonical NFkB pathway upon activation
of the B-cell receptor (BCR; Avramidou et al., 2007; Hagen et al.,
2012; Kim et al., 2013). ShRNA-mediated EFhd2 knockdown
led to increase IkB phosphorylation, which is a prerequisite
for translocation of NFkB to the nucleus, upon BCR activation
(Avramidou et al., 2007; Kim et al., 2013). Based on this result,
the authors suggested that EFhd2 may play a role as negative
regulator of NFkB in the BCR signaling pathway (Avramidou
et al., 2007). Alternatively, another study found EFhd2 at the
plasma membrane, where it facilitates the assembly of the
BCR and appears to work as a scaffold protein required for
the function of Syk, SLP-65, and PLCγ2 during BCR-induced
calcium flux (Kroczek et al., 2010). The functional interaction
of EFhd2 with BCR signaling pathway and modulation of
IkB phosphorylation indicates a potential regulatory role in
cell survival or fate. Interestingly, EFhd2 was identified as a
novel pro-caspase-9-interacting protein in H460 cells (Che˛cin´ska
et al., 2009). EFhd2 association with (inactive) pro-caspase-9
protein suggests that it may regulate the activation of apoptosis
(Che˛cin´ska et al., 2009). In contrast, other reports indicated that
EFhd2 mediates actin bundling and regulates cell spreading and
migration (Huh et al., 2013; Kwon et al., 2013). Moreover, recent
studies indicated that EFhd2 was upregulated by epidermal
growth factor signaling and mediates cell migration through the
modulation of Rac1, Cdc42, and RhoA activity (Huh et al., 2015).
Although, the direct role of EFhd2 in regulating cellular survival
and apoptosis is still unclear, these results indicate that this novel
protein plays an important role in modulating cellular responses
elicited by different environmental cues, such as trophic factors
or stimulating antibodies (Avramidou et al., 2007; Huh et al.,
2015).
EFhd2 has also been associated with different pathological
processes, from cancer to neurological disorders (Table 1). In
cancer, EFhd2 was found to be overexpressed in the majority of
carcinomas, colon cancer, and melanoma (Huh et al., 2015). The
results indicated that EFhd2maymediate invasion andmetastasis
of cancerous cells, suggesting it plays an important role in the
biology of cancer. EFhd2 gene expression and protein abundance
have been also shown to be altered in AD and other neurological
disorders. Thus, even though the role that EFhd2 plays in cancer
biology is of great interest, this review focusses on EFhd2’s role
in the central nervous system, specifically its association with AD
and other neurological disorders.
IS EFHD2 A MODULATOR OF
FUNCTIONAL SYNAPSE FORMATION?
EFhd2 is highly expressed in neurons compared to other cell
types of the central nervous system, where may play an important
role in synapse formation (Reynolds et al., 2008; Vega et al., 2008;
Ferrer-Acosta et al., 2013b; Borger et al., 2014). EFhd2 proteins
were found in the cytosol and proximal to the membrane in
neurons of most brain regions, including higher expression in
the deeper layers of the cortex and hippocampus (Ferrer-Acosta
et al., 2013b; Borger et al., 2014). EFhd2 co-localized with neurite
markers such as tau,MAP2, synapsin, and PSD95, suggesting that
its neuronal function could be associated with vesicle transport
and synapse homeostasis (Borger et al., 2014; Purohit et al., 2014).
Consistent with this putative function, a recent study showed in
vitro that knockdown of EFhd2 increased synpasin 1a/b puncta
labeling in neurites, suggesting that modulation of EFhd2 affects
the development of functional synapses, but it had no effect on
converting them to mature synapses as determined by the co-
localization of synapsin and PSD95 (Borger et al., 2014). These
results imply that EFhd2 may modulate the formation of new
synapses, a process that it is relevant for different brain functions,
such as learning and memory.
Characterization of an Efhd2 knockout mouse provided
further insights about its function in the central nervous system.
Purohit et al. (2014) showed that deletion of Efhd2 gene has
no detectable effect on brain anatomy or function. Interestingly,
they showed that vesicle transport velocity was enhanced in
Efhd2(−/−) knockout primary hippocampal neurons and that
EFhd2 protein inhibited kinesin mediated microtubule gliding in
vitro (Purohit et al., 2014). The authors proposed that EFhd2may
interfere with the interaction between kinesin and microtubules
(Purohit et al., 2014). In this regard, EFhd2 has been showed
to co-purify with tubulin in the synaptosome fraction as well
as to mediate actin bundling (Huh et al., 2013; Kwon et al.,
2013; Purohit et al., 2014). Although, there is no evidence that
Efhd2 gene knockout affects brain function, these results suggest
that EFhd2 may serve as a modulator of synapse formation
by regulating the velocity of vesicle transport and cytoskeleton
rearrangement.
EFHD2 IN ALZHEIMER’S DISEASE
EFhd2 protein abundance was found altered in AD, suggesting
that Efhd2 gene expression may be regulated in response to
neurodegeneration (Vega et al., 2008; Borger et al., 2014;Table 1).
Two different studies showed that the chromosome region
encompassing the Efhd2 gene locus is linked to (and a third
study showed that it is associated with) late-onset Alzheimer’s
disease (LOAD; Hiltunen et al., 2001; Myers et al., 2002; Holmans
et al., 2005). The linkage between Efhd2 gene and LOAD is
yet to be determined; however, we and others have shown that
EFhd2 expression and protein abundance is altered in AD and
Frontiers in Neuroscience | www.frontiersin.org 2 March 2016 | Volume 10 | Article 150
Vega EFhd2, a Neurodegenerative or Neuroprotective Protein?
TABLE 1 | Identification of EFhd2 associated with neurological disorders.
Disorders Disease Results Summary Method References
Movement Parkinson’s disease
(PD)
EFhd2 was found to be secreted from microglia after
exposure to nitrated α-syn
SELDI-TOF ProteinChip Reynolds et al., 2008
EFhd2 protein abundance was shown to be reduced in
midbrain (substantia nigra) of PINK1-KO mice
2D-DIGE and Tandem
Mass Spectrometry
Diedrich et al., 2011
EFhd2 was identified as Lrrk2 interacting protein,






Meixner et al., 2011
EFhd2 increased expression correlates with IFN-γ and
SNCA switch to positive co-expression in substantia
nigra in PD cases gathered from four different
datasets; relationship between inflammation and PD




EFhd2 was one of the proteins uniquely identified in
lipid raft isolated from mouse overexpressing G93A
mutant SOD1
2D-gel and Tandem Mass
Spectrometry
Zhai et al., 2009





May et al., 2014
Huntington’s
disease
EFhd2 down-regulation preceded phenotype onset
and it was one of only nine identified proteins with
sustained altered expression after onset in a mouse
model for Huntington’s disease
2D-gel and Tandem Mass
Spectrometry




Suicide EFhd2 was found down-regulated in prefrontal cortex




Kékesi et al., 2012
Schizophrenia EFhd2 protein was found up-regulated in dorsolateral





EFhd2 protein was found up-regulated in postmortem









EFhd2 was shown to co-immunoprecipitate with tau
proteins in temporal cortex derived from AD and FTDP





Vega et al., 2008
EFhd2 is found overexpressed in AD (APP23) and
stroke (pMCAO) mouse models
Microarray Tseveleki et al., 2010
Increased alternative splicing of EFhd2 in frontal cortex
of AD patients in comparison to normal aging
RNA-Seq Twine et al., 2011
EFhd2 was found associated with tau aggregates in
the somatodendritic compartment and co-purified with
tau filaments; EFhd2 protein abundance also found




Ferrer-Acosta et al., 2013b
EFhd2 protein levels were found reduced in frontal
cortices from different types of tauopathies and other
dementias
Immunoblotting Borger et al., 2014
animal models that mimic the pathophysiology associated with
AD (Vega et al., 2008; Tseveleki et al., 2010; Borger et al., 2014).
Previously, we showed that EFhd2 protein is increased in the
tauopathy mouse model JNPL3, which expresses the human
P301L mutant tau protein (Vega et al., 2008; Ferrer-Acosta et al.,
2013b). We showed that EFhd2 protein abundance increased
as the accumulation of pathological tau and progression of the
motor impairment phenotype augmented in JNPL3 mice (Vega
et al., 2008). In an independent expression profiling study, using
a different AD mouse model, APP23, EFhd2 was also found
to be overexpressed (Tseveleki et al., 2010). It is important to
mention that the APP23 AD mouse model overexpresses human
Amyloid Precursor Protein with double Swedish mutation
(K670M/N671L) and it has been shown that tau mediates the
toxicity observed in this mouse model (Sturchler-Pierrat et al.,
1997; Ittner et al., 2010). These results suggest that EFhd2 is up-
regulated in response to pathological processes associated with
tau-mediated neurodegeneration.
EFhd2 protein increased abundance in mouse models
of neurodegeneration was validated in postmortem AD
brain (Vega et al., 2008; Ferrer-Acosta et al., 2013b). Using
quantitative immunoblotting, we demonstrated that EFhd2
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protein abundance is increased in postmortem frontal cortices
in AD cases (Ferrer-Acosta et al., 2013b). In contrast, Borger
et al. (2014) showed that EFhd2 protein abundance is reduced in
AD cases and other dementias, including frontotemporal lobar
degeneration with TDP43 pathology. Moreover, they showed
that EFhd2 mRNA was also significantly lower in AD, when
compare to normal aging controls. The discrepancy between
these two reports could be due to differences in postmortem
brain sample selection, agonal stage, activated glial cells, and/or
differential immune cell infiltration. For example, in our study,
we included only AD postmortem brain with Braak stage IV
or higher (Ferrer-Acosta et al., 2013b). In Borger et al. (2014),
Braak stage is reported for only a few of the cases used. It is
important to mention that in those reported cases with Braak
stage VI, EFhd2 protein level is higher than in the other AD cases
that the Braak stage was not indicated. Other technical reasons,
such as anti-EFhd2 antibodies used, protein extraction method
and differential subcellular localization, could contribute to the
discrepancy. Interestingly, Twine et al. (2011) identified EFhd2
as one of the genes with increased alternative splicing in frontal
cortices of AD patients. This is consistent with previous results
that identified two protein bands corresponding to EFhd2, which
might contribute to the detection of different EFhd2 isoforms
depending on the antibody used (Avramidou et al., 2007; Vega
et al., 2008). Nevertheless, what is consistent among these studies
is that EFhd2 expression was found altered in AD. Further
studies are required to determine the molecular mechanisms
involved in the regulation of the Efhd2 gene and protein under
pathological or cellular stress conditions.
Further biochemical characterization of EFhd2 protein
demonstrated that this novel protein has the molecular and
structural features of amyloid proteins (Ferrer-Acosta et al.,
2013b). In vitro studies showed that Thioflavin S (a dye that
selectively binds to amyloid structures) binds recombinant
EFhd2 protein, indicating that EFhd2 transition from a mostly
helical and random coil structure to cross-beta-sheet (Ferrer-
Acosta et al., 2013a,b). Amyloid proteins tend to form
oligomers and filamentous structures. Electron microscopy
analyses confirmed that EFhd2 forms filaments in vitro without
the requirement of a nucleation factor (Congdon et al., 2008;
Ferrer-Acosta et al., 2013b). Furthermore, the presence of
calcium reduces EFhd2’s ability to form filaments, and the coiled-
coil domain was shown to be required for the formation of
EFhd2 homodimers (Ferrer-Acosta et al., 2013b). These results
indicated that formation of EFhd2 filaments could promote
the association with pathological tau filaments. To test this
hypothesis, immunohistological analyses of AD brain slices
were performed. The results showed that EFhd2 co-localized
with PHF1 (an antibody that recognized tau filaments) in
the somatodendritic compartment, validating the association
of EFhd2 with filamentous tau structures (Ferrer-Acosta et al.,
2013b). Moreover, immune-gold electron microscopy showed
that EFhd2 and tau, purified from AD brain, formed co-filaments
(Ferrer-Acosta et al., 2013b). Moreover, in vitro protein–protein
interaction assays demonstrated that EFhd2’s coiled-coil domain
is necessary for its association with tau proteins purified from
brain extract derived from JNPL3 mice (Ferrer-Acosta et al.,
2013b). Thus, it is plausible to hypothesize that formation
of EFhd2 oligomers may serve as nucleation factor for tau
oligomerization and, consequently, NFTs in AD and other
tauopathies (Figure 1). Nevertheless, further studies are required
to determine EFhd2’s capability to enhance protein aggregation
in tauopathy and other neurodegenerative disorders.
EFHD2 IS ASSOCIATED WITH
PARKINSON’S DISEASE AND OTHER
NEUROLOGICAL DISORDERS
EFhd2 has been also found associated with Parkinson’s
disease (PD). Liscovitch and French (2014) showed that
EFhd2 expression is increased in substantia nigra in PD. In
this study, they found that EFhd2 overexpression correlated
with the positive co-expression of α-synuclein and IFN-
γ, establishing a molecular relationship between PD and
inflammation (Liscovitch and French, 2014;Table 1). In contrast,
EFhd2 protein abundance was found reduced in the substantia
nigra of a mouse model where PTEN-induced kinase 1
(PINK1) has been knockout (Diedrich et al., 2011). PINK1 is a
mitochondrial protein, the loss-of-function mutation of which
induces early-onset PD. These conflicting reports could be due
to the difference between mechanisms associated with sporadic
PD cases and those underlying the phenotype of the PINK1
knockout mice. However, in vitro studies identified EFhd2 as a
protein secreted/released by microglia cells upon incubation with
nitrated α-synuclein (Reynolds et al., 2008). This is the first study
that shows expression of EFhd2 in microglia cells, but, more
importantly, it also indicates that EFhd2, a cytosolic protein,
could be released from cells in response to a pathological signal.
Taken together, EFhd2 altered protein abundance in PD provides
strong evidence that it is involved in molecular mechanisms
associated with neurodegeneration.
EFhd2 associates with known proteins linked to the
pathophysiology of PD (Table 1). In a proteomics approach,
EFhd2 was identified associated with leucine-rich repeat kinase
2 (Lrrk2), the most common causative gene of inherited PD
(Meixner et al., 2011). Interestingly, this study demonstrated
that Lrrk2 decreased actin polymerization, promoting the
accumulation of monomeric actin (G-actin; Meixner et al., 2011).
Knockdown of Lrrk2 affects actin cytoskeleton and cellular
morphology, indicating that Lrrk2 plays a direct role on actin
(Meixner et al., 2011). In contrast, EFhd2 promotes actin
bundling (Huh et al., 2013). Thus, these results suggest that Lrrk2
and EFhd2 may compete for the interaction with F-actin, as
regulators of actin cytoskeleton dynamics. Moreover, Lrrk2 has
been shown to phosphorylate tau and promote tau aggregation,
as observed in postmortem brain tissue from PD cases with Lrrk2
mutations (Guerreiro et al., 2015). On the basis of their link to
neurodegeneration, it is reasonable to speculate that there could
be a pathological connection between Lrrk2 and tau through
EFhd2.
EFhd2 altered protein abundance and its association with
pathological proteins have also been found in other neurological
disorders. EFhd2 protein was identified as a co-aggregating
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FIGURE 1 | Working hypothesis: EFhd2 role in neurodegeneration. (1) Activation: Pathological signals, such accumulation of Aβ oligomers, calcium influx, and
neuroinflammation, lead to the activation of specific kinases, such as GSK3β and Cdk5/p25, and upregulation of gene expression. These kinases mediate the
hyperphosphorylation of tau proteins and promote its release from the microtubules (MTs). Altered expression of Efhd2 gene leads to increase abundance of EFhd2
protein. (2) Oligomerization: The accumulation of EFhd2 proteins and its self-oligomerization properties could serve as a nucleation factor for hyperphosphorylated tau
proteins, enhancing the kinetics of the formation of tau oligomers and/or neurofibrillary tangles at the somatodendritic compartment. Additionally, the accumulation of
EFhd2 proteins affects kinesin-mediated fast axonal transport and promotes actin-bundling. (3) Toxicity: The accumulation of EFhd2 and tau oligomers leads to
neuronal death and its release to the interstitial fluid, where are up-taken by neighboring neurons. Alternatively, EFhd2 could accelerate the transition from tau
oligomers to neurofibrillary tangles (NFTs) as a neuroprotective mechanism, reducing the capacity of toxic tau transmission. Further studies are required to define the
pathological role of EFhd2 in AD and other neurological disorders.
protein with poly-GA C9orf72, a common pathogenic protein
in amyotrophic lateral sclerosis (ALS) and frontotemporal lobar
degeneration (FTLD; May et al., 2014). This result suggests
that EFhd2 may be involved in the molecular mechanisms that
lead to aggregation of pathological proteins, other than tau, in
proteinopathies such as ALS. Consistently, EFhd2 was one of the
uniquely identified proteins found in lipid rafts isolated from a
mouse model that expresses the G93A SOD1 mutant; a mutation
found in inherited ALS cases (Zhai et al., 2009). This result
indicates that EFhd2 subcellular localization could also be altered
in neurodegeneration.
In addition to its association with neurodegenerative diseases,
Efhd2 gene expression has also been found altered in psychiatric
disorders. Two independent studies demonstrated that EFhd2
is up-regulated in schizophrenia (Martins-de-Souza et al., 2009,
2010). Postmortem analysis of dorsolateral prefrontal cortex and
mediodorsal thalamus, two brain regions associated with the
pathophysiology of schizophrenia, revealed a significant increase
in EFhd2 protein level in comparison to normal control cases
(Martins-de-Souza et al., 2009, 2010). In contrast, EFhd2 was
found down-regulated in prefrontal cortex and up-regulated in
amygdala of individuals that committed suicide (Kékesi et al.,
2012). These results suggest that altered levels of EFhd2 are
directly associated with brain pathology.
CONCLUSION
In summary, EFhd2 harbors similarities to known and well-
studied neuropathological proteins. For instance, EFhd2 is a
structural disorder protein mainly composed of random coils
and alpha helices, forms filamentous structures, associates with
vesicle trafficking and cytoskeleton rearrangement, co-aggregate,
and co-purify with pathological proteins, its expression and
protein abundance is altered in neurodegenerative diseases.
Based on these similarities and the published results discussed
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above, it is plausible to hypothesize that neuronal stress due
to environmental cues (such as cytokines) or pathological
protein aggregation induces changes in Efhd2 gene expression
(Figure 1). In this context, activation of signaling proteins, such
as Cdk5 (Vázquez-Rosa et al., 2014), induces posttranslational
modifications on EFhd2 that affect its calcium binding activity
and promotes self-oligomerization (Figure 1). The accumulation
of EFhd2 oligomers could serve as a nucleation factor of tau
proteins facilitating its accumulation at the somatodendritic
compartment, which also affects kinesin-mediated fast axonal
transport (Figure 1; Kanaan et al., 2013). Consequently, the
accumulation of EFhd2 proteins and tau aggregates would lead
to activation of apoptosis (Figure 1). Interestingly, up-regulation
of EFhd2 could also promote aberrant actin bundling, leading to
the formation of Hirano bodies in AD (Figure 1, Sonoda et al.,
2015).
Alternatively, EFhd2 altered expression in neurological
disorders could be related to neuroprotection. The identification
of EFhd2 co-localization with neurofibrillary tangles (NFTs)
in the somatodendric compartment and its filament formation
capability suggest that EFhd2 may affect the kinetic of
tau filament formation, promoting the generation of
stable ultrastructures (Figure 1). The generation of NFTs
may sequester tau oligomers, preventing the spread of
toxic tau to the interstitial fluid. Concomitantly, EFhd2’s
accumulation in NFTs induces a loss-of-function effect
that promotes the generation of new functional synapses
through increase vesicle transport velocity similar to that
observed in Efhd2 knockout mice. This may explain why NFT
bearing neurons are still synaptically active and functionally
integrated in neuronal circuits (Kuchibhotla et al., 2014).
Nevertheless, further studies are crucial to determine the
role that EFhd2 plays in the pathophysiology of neurological
disorders.
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